Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Series B Preferred Stock [Member]	Total
Balance at Dec. 31, 2018	$ 15,000	$ 230,754,000	$ (219,461,000)	$ (2,909,000)	$ 5,760,000	$ (14,159,000)
Balance (in shares) at Dec. 31, 2018	15,482,083				9,161
Stock-based compensation		64,000				64,000
Series A Preferred Stock Dividends			(61,000)			(61,000)
Issuance of SYN Biomics Stock		(36,000)		53,000		17,000
Conversion of Series B Preferred Stock to Common	$ 1,000	1,035,000	(398,000)		$ (638,000)
Conversion of Series B Preferred Stock to Common (in shares)	900,869				(1,036)
Net loss			(3,512,000)			(3,512,000)
Non-controlling interest				(16,000)		(16,000)
Balance at Mar. 31, 2019	$ 16,000	231,817,000	(223,432,000)	(2,872,000)	$ 5,122,000	10,651,000
Balance (in shares) at Mar. 31, 2019	16,382,952				8,125
Balance at Dec. 31, 2018	$ 15,000	230,754,000	(219,461,000)	(2,909,000)	$ 5,760,000	(14,159,000)
Balance (in shares) at Dec. 31, 2018	15,482,083				9,161
Balance at Dec. 31, 2019	$ 17,000	232,580,000	(235,537,000)	(2,878,000)	$ 4,761,000	(1,057,000)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638
Stock-based compensation	$ 0	83,000	0	0	$ 0	83,000
Series A Preferred Stock Dividends	0	0	(62,000)	0	0	(62,000)
Issuance of SYN Biomics Stock	0	0	0	26,000	0	26,000
Conversion of Series B Preferred Stock to Common	$ 1,000	1,072,000	(404,000)	0	$ (669,000)	0
Conversion of Series B Preferred Stock to Common (in shares)	933,045				(1,073)
Net loss	$ 0	0	(2,964,000)	0	$ 0	(2,964,000)
Non-controlling interest	0	0	0	(26,000)	0	(26,000)
Balance at Mar. 31, 2020	$ 18,000	$ 233,735,000	$ (238,967,000)	$ (2,878,000)	$ 4,092,000	$ (4,000,000)
Balance (in shares) at Mar. 31, 2020	17,739,475				6,565